The procoagulant effects of fine particulate matter in vivo

Evren Kilinc*, Holger Schulz, Gerhardus J. A. J. M. Kuiper, Henri M. H. Spronk, Hugo ten Cate, Swapna Upadhyay, Koustav Ganguly, Tobias Stoeger, Manuela Semmler-Bhenke, Shinji Takenaka, Wolfgang G. Kreyling, Mike Pitz, Peter Reitmeir, Annette Peters, Oliver Eickelberg, H Erich Wichmann

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Inhalation of fine particulate matter (<2.5 mu m; fine PM) has been shown to increase the risk for cardiovascular events. In this letter, we reappraise the role of tissue factor (TF) antigen and we also summarize changes in measured coagulation proteins in humans and rodents by other studies with fine PM. By considering all studies including ours, we conclude that monitoring the overall coagulation state by measuring capacity assays such as thrombin generation, and quantification of TF activity would be more suitable than determining single coagulation proteins (such as TF antigen) in order to better assess the systemic prothrombotic effects of fine PM.
Original languageEnglish
Pages (from-to)3
JournalParticle and Fibre Toxicology
Publication statusPublished - 15 Mar 2011

Cite this